Variantyx is a leading genomics company specializing in advanced diagnostic testing and genomic analysis to produce personalized medicines. Utilizing state-of-the-art sequencing technologies and bioinformatics tools, Variantyx offers comprehensive genetic testing services aimed at identifying and characterizing complex genetic variations. Their scientific approach enables precise diagnosis of rare and inherited disorders, providing clinicians and patients with valuable insights into genetic disease mechanisms. Variantyx leverages the power of whole genome and other new sequencing technologies, along with intelligent analysis technology for prenatal testing, rare genetic disorder diagnosis, precision oncology treatment, and even wellness testing for healthy adults.

Variantyx

Utilization Review Manager- Genetic Counselor

Software Engineer

We're coming to Arizona, North Carolina, Virginia and Illinois today! If you're attending one of these regional genetic counselor events, we'd love to chat about your work and how our comprehensive whole genome testing is designed to uncover more answers for patients. Stop by and visit with our specialists!


                                        View                                    

A patient presents with signs of hereditary neuropathy. Is it CMT? HNPP? Something else?  🤔

Traditional sequential genetic tests can miss key variants.

Our Genomic Unity® Neuropathies Analysis uses the power of whole genome sequencing to provide the most comprehensive testing available. This test:
✔️Targets 103 genes linked to inherited neuropathies
✔️Automatically reflexes to full genome analysis if initial findings are inconclusive
✔️Detects variants of all sizes -  from single base changes to complex structural changes including CNVs and repeat expansions in RFC1, ZFHX3 and more.

Technology matters. Choose wisely. Choose Variantyx.

Learn more ➡️ https://ow.ly/YjNf50VR6Xh 

#NeuropathyAwareness #PeripheralNeuropathyAwareness #NeuropathyAwarenessWeek #CMT #WeSeeMore


 Variantyx scoops up $20M for whole genome sequencing-based testing methodology 

Daryl Spinner, Variantyx

When it comes to patient care, comprehensive genetic testing isn’t just an option – it’s a necessity. Genomic Unity® 2.0 is the gold standard in whole genome sequencing, providing the deepest insights into every aspect of a patient’s genetic makeup.

Why choose Variantyx?
✔️ Dual Sequencing Power: We combine both short-read and long-read sequencing, ensuring no detail is overlooked.
✔️ Full Variant Detection: From single nucleotide changes to structural variants, repeat expansions, methylation patterns, and more.
✔️ Unmatched Depth & Accuracy – Our advanced technology provides the highest coverage and reliability in genetic analysis.

Your patients deserve answers that lead to the best possible care. At Variantyx, we deliver the most complete genomic insights – every time. Learn more at https://ow.ly/ECxJ50VCBZh

#ComprehensiveGenetics #GenomicUnity #WholeGenomeSequencing #PatientCare #HealthcareInnovation #Variantyx #WeSeeMore #GenomicExcellence #ChooseWisely #ChooseGenome #ChooseVariantyx #WeSeeMore


This #LabWeek, we’re shining a spotlight on the hard work of our dedicated lab professionals! Their behind-the-scenes contributions are essential in delivering accurate, timely test results. Thank you for all that you do!

 Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders 

We're looking forward Christine Stanley's #NSGC24 lunch symposia tomorrow on the next evolution in genomic testing. Can't make it? Come see us at booth 426.

At Variantyx, we’re committed to providing the most comprehensive solutions for genetic analysis. Our Genomic Unity 2.0® can now detect 44 repeat expansions, setting a new standard in genetic testing. 

Meanwhile, our whole genome testing continues to lead the way with coverage of 37 repeat expansion genes—the highest number of genes analyzed in one test! This approach ensures that we capture a broad spectrum of clinically relevant repeat expansions with unparalleled accuracy.

With cutting-edge technology and a whole genome perspective, we’re pushing the boundaries of genetic diagnostics to provide deeper insights for patients and clinicians alike.

Ensure your patients receive the most accurate diagnosis possible – choose Variantyx.
#Genomics #RepeatExpansions #PrecisionMedicine #Variantyx #WholeGenomeTesting

Learn more at https://ow.ly/vhLe50VCBAN

 Variantyx–SEVERAL: investment, 202404 financing round $36m from existing investors 

At Variantyx, our whole genome platform powers the most comprehensive genetic testing available — from targeted analysis to comprehensive whole genome analysis with or without  long-read, all within our Genomic Unity® suite.

With IriSight®, our prenatal test, we’re the only prenatal diagnostic lab that covers small sequence changes, structural variants of all sizes, mitochondrial genome and analysis of short tandem repeat in one test, one sample, with a TAT under 14 days.

Come visit us at FLAGC, May 29–30 in Gainesville, Florida

Let’s talk about how we can support your patients with deeper, more complete genetic testing. 

#Genomics #WholeGenomeSequencing #PrenatalTesting #PrecisionMedicine #FLAGC2025 #Variantyx #WGS


Variantyx Launches Genomic Intelligence® Clinical Diagnostic Platform - Business Wire

 Framingham firm debuts genome test to check for genetic ... 

 Variantyx: Molecular Diagnostics Company Closes $36 Million In Funding 

 Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint 


								Variantyx updates secondary findings reporting policy to ACMG v3.2									

 Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase 


								Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint									

 Variantyx: Genomic Precision Medicine Company To Expand With New Funding Round 

 Robert Bosch Venture Capital Invests Approx. $26M in Variantyx 

We were pleased to conclude DNA Day with Christine Stanley, FACMG’s compelling presentation at ISGP. 

Thank you to all the participants—it was a pleasure speaking with you!

 Variantyx Raises $41.5M in Second Series C Funding Round 

The Variantyx Difference

 Outsized Closes Series A Funding 

Viome Life Sciences raises $67M and more digital health fundings - MobiHealthNews

Variantyx Launches Its RareDx Program, Providing Clinical Whole Genome Testing to Enrolled Patients - Business Wire

Whole-genome analysis company Variantyx gets $41.5M for precision oncology solutions - Fierce healthcare


					


	
	
	
	
	
	
	
	
	
	

					Variantyx
					
				

Exciting news! Our Lightning rapid genome test is now available for patients of all ages. Choose from neonatal, pediatric and standard analysis offerings. All three are lightning fast, ensuring timely answers to guide medical management. Learn more here -> https://lnkd.in/eXyxG-UH

Learn More About Mitochondrial Disorder Testing With Variantyx

Variantyx debuts whole genome sequencing prenatal test - Labpulse

 Variantyx Raises $36M in Funding 

Today we celebrate genetic counselors everywhere! Thank you for the support you provide to patients and their families. #GCawareness #GeneticCounselorAwarenessDay

Israel's all-in-one test for diagnosis of rare inherited disorders - The Jerusalem Post

Learn More About Ataxia Testing With Variantyx

Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Business Wire

#NiemannPick awareness month is off to a positive start with the FDA’s recent approval of two Type C treatments: Aqneursa and Miplyffa. For the most comprehensive analysis of NPC1 and NPC2 genes available, choose Genomic Unity #wholegenome testing. Learn more about the Variantyx difference ➡️ https://lnkd.in/eETwQujq

#WeSeeMore

 Wellness Genomics Market Report 2025 – For Strategy Officers And Market Intelligence Teams 

Peregrine Ventures: Israel’s most active investor in health tech venture capital investments - The Jerusalem Post

 Variantyx Raises Additional Funding 

Robert Bosch Venture Capital joins Variantyx’s US $26 million Series C funding round - bosch-presse.de

Watch to see how Genomic Unity® whole genome testing made a Segawa syndrome diagnosis following multiple negative tests using other technologies  ▶️  https://ow.ly/WGXH50TIUNY

With treatment options available for #RettSyndrome, comprehensive identification of MECP2 variants through #wholegenome testing has become even more important. Download our case study describing a partial exon MECP2 deletion to see why Seeing More with Variantyx testing makes a difference 🔎 https://ow.ly/um6750TMKW9

It's been one month since we launched Genomic Unity® 2.0 and the response has been amazing. See why everyone is talking about our new combined short and long-read genome sequencing test  ➡️  https://lnkd.in/eGsD7E4i

Variantyx Secures $41.5M in Series C-2 Funding - FinSMEs

Daryl Spinner, Variantyx - Fierce Pharma

Next week, our team is heading to Arizona, Virginia, North Carolina, and Illinois for regional genetic counselor events — and we can't wait to connect.

If you're attending, come say hello! We'd love to hear about your work and share how our comprehensive whole genome testing is helping uncover more answers for patients and families. Stop by and visit with our specialists!



								Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders									

 Technology-Driven Precision Medicine Company Variantyx Secures $41.5M in Funding 

Robert Bosch Venture Capital Invests Approx. $26M in Variantyx - FinSMEs

We’re proud to contribute to a cleaner planet! By using uncoated cardboard, we ensure that thousands of our used sample kits are recycled instead of ending up in landfills. Every small step counts!

Variantyx Lands $20M for Whole Genome Sequencing Methodology - HIT Consultant

Variantyx raises $36m to commercialise genomic diagnostics - Yahoo Finance

 Robert Bosch Venture Capital joins Variantyx's US $26 million Series C funding round 

Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint - Business Wire

Thanks to the comprehensive analysis power of IriSight™ #wholegenome testing, we find that ~6% of prenatal cases result in a dual diagnosis. Download our latest prenatal case study to see how a mix of small sequence changes and single exon deletions was uniquely detected in a single test 👉 https://ow.ly/hLL450T8ZkR

Explore rapid testing with Variantyx


								Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis									

Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0 - Business Wire


								Variantyx Combines Long and Short Reads for Rare Disease Whole-Genome Diagnostic Test									

Variantyx raises $36m to commercialise genomic diagnostics - Medical Device Network

Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders - Business Wire

 8 Whole Genome Sequencing Companies for Precision Health 

ONT long-read WGS for variant discovery and orthogonal confirmation of short read WGS derived genetic variants in clinical genetic testing - Frontiers

Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders - Business Wire


								Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0									

Learn More About Epilepsy Testing With Variantyx

Variantyx and FDNA Announce Integration of their Applications to Facilitate Rare Disease Diagnosis - Business Wire

Join us today and tomorrow at the Virginia State Genetics Education Conference (VaAGC), where we’ll be connecting with genetic counselors and professionals across the region.
We’re excited to share how our whole genome testing is helping uncover more clinically relevant answers for patients — and to hear about your work! Swing by our table to chat with our team — we’d love to connect!

The next evolution of genomic testing is here. Today! Read the press release 🧬 Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0 👉 https://lnkd.in/es73ib_W

If you're at #NSGC24, stop by Variantyx booth 426 to find out more about Genomic Unity 2.0 - the ultimate diagnostic test.

 Variantyx raises $36m to commercialise genomic diagnostics 

Check out this week's GenomeWeb article featuring Genomic Unity® 2.0 combined short and long-read genome sequencing 🧬 https://lnkd.in/ew4NrCzy

 Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference 

 Variantyx Raises $36M in Private Financing 

Understanding Variantyx Reports

 Variantyx Secures $20M in Series C 


								Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase									

Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase - Business Wire

Variantyx

About: